Preliminary data on immunogenicity, safety and tolerability of trivalent inactivated influenza vaccine in children with inborn errors of metabolism at risk of decompensation

Highlights • Trivalent influenza vaccine is immunogenic in children with inborn errors of metabolism. • Trivalent influenza vaccine is safe in children with inborn errors of metabolism. • Influenza vaccination is recommended in children with inborn errors of metabolism.

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Vaccine 2013-10, Vol.31 (45), p.5149-5151
Hauptverfasser:	Esposito, Susanna, Salvini, Filippo, Menni, Francesca, Scala, Alessia, Salvatici, Elisabetta, Manzoni, Francesca, Riva, Enrica, Giovannini, Marcello, Principi, Nicola
Format:	Artikel
Sprache:	eng
Schlagworte:	Adolescent Allergy and Immunology Antibodies, Viral - blood Applied microbiology Biological and medical sciences Child Child, Preschool Children Disease Drug-Related Side Effects and Adverse Reactions - epidemiology Drug-Related Side Effects and Adverse Reactions - pathology Female Fundamental and applied biological sciences. Psychology Hospitals Humans Immunogenicity Influenza Influenza vaccine Influenza Vaccines - administration & dosage Influenza Vaccines - adverse effects Influenza Vaccines - immunology Influenza virus Influenza, Human - prevention & control Male Metabolic disease Metabolism Metabolism, Inborn Errors - complications Metabolism, Inborn Errors - immunology Microbiology Miscellaneous Safety Trivalent influenza vaccine Vaccines Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies (general aspects) Virology
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Highlights • Trivalent influenza vaccine is immunogenic in children with inborn errors of metabolism. • Trivalent influenza vaccine is safe in children with inborn errors of metabolism. • Influenza vaccination is recommended in children with inborn errors of metabolism.
ISSN:	0264-410X 1873-2518
DOI:	10.1016/j.vaccine.2013.08.058